Cargando…

Prospects of siponimod in secondary progressive multiple sclerosis

Detalles Bibliográficos
Autores principales:	McGinley, Marisa, Fox, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050809/ https://www.ncbi.nlm.nih.gov/pubmed/30038666 http://dx.doi.org/10.1177/1756286418788013

Ejemplares similares

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Siponimod for multiple sclerosis
Publicado: (2021)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
por: Gajofatto, Alberto
Publicado: (2017)

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
por: Krbot Skorić, Magdalena, et al.
Publicado: (2022)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod
por: Senzaki, Kensuke, et al.
Publicado: (2021)

Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence
por: Sabsabi, Sajida, et al.
Publicado: (2022)

Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
por: Abbadessa, Gianmarco, et al.
Publicado: (2022)

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
por: Gold, Ralf, et al.
Publicado: (2022)

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
por: Cree, Bruce AC, et al.
Publicado: (2022)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016)

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2022)

Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis
por: Song, Yumeng, et al.
Publicado: (2019)

First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod
por: Starke, Ludger, et al.
Publicado: (2023)

The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
por: Arnold, Douglas L, et al.
Publicado: (2022)

Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland
por: Schur, Nadine, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials
por: Chaoyang, Chen, et al.
Publicado: (2022)

Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review
por: Li, Qingsheng, et al.
Publicado: (2023)

Expanded access to multiple sclerosis teleneurology care following the COVID-19 pandemic
por: McGinley, Marisa P, et al.
Publicado: (2021)

Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod
por: Siddiqui, Gulnaz, et al.
Publicado: (2021)

Gadolinium‐based contrast agent exposures and physical and cognitive disability in multiple sclerosis
por: Nakamura, Kunio, et al.
Publicado: (2022)

Providing Person-Centered Care via Telemedicine in the Era of COVID-19 in Multiple Sclerosis
por: Abbatemarco, Justin R, et al.
Publicado: (2021)

Secondary Progressive Multiple Sclerosis: New Insights
por: Cree, Bruce A.C., et al.
Publicado: (2021)

Siponimod ameliorates experimental autoimmune neuritis
por: Uchi, Takafumi, et al.
Publicado: (2023)

Therapeutic effect of combination vitamin D3 and siponimod on remyelination and modulate microglia activation in cuprizone mouse model of multiple sclerosis
por: Al-Otaibi, Kholoud M., et al.
Publicado: (2023)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
por: Behrangi, Newshan, et al.
Publicado: (2019)

Leucine-Rich Glioma Inactivated-1 and Voltage-Gated Potassium Channel Autoimmune Encephalitis Associated with Ischemic Stroke: A Case Report
por: McGinley, Marisa, et al.
Publicado: (2016)

Does Siponimod Exert Direct Effects in the Central Nervous System?
por: Kipp, Markus
Publicado: (2020)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation
por: Gruchot, Joel, et al.
Publicado: (2022)

Progress and Roadblocks Along the Pathway to Multiple Sclerosis Treatment
Publicado: (2015)

Serum neurofilament light chain predicts cognitive worsening in secondary progressive multiple sclerosis better than brain MRI measures
por: Gaetani, Lorenzo, et al.
Publicado: (2022)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hq9cibrj0adkcu5s2d6qelm9ms